Li-Mei Han

Li-Mei Han

Auto-generated profile, based on publicly available information

Li-Mei Han

Clinical Research Center, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2024 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
WWWei-Xiao Wang
Wei-Xiao Wang
JWJiazhen Wu
Jiazhen Wu
BZBai-Ling Zhang
Bai-Ling Zhang
JYJiao-Yang Yu
Jiao-Yang Yu
LHLi-Mei Han
Li-Mei Han
Wei ChenWei Chen
Wei Chen

1 August 2022 in Journal of Biomaterials and Tissue Engineering
Verified
Journal Article
Closed access
JWJun Wu
Jun Wu
YXYingying Xie
Yingying Xie
LHLimei Han
Limei Han
This study assessed whether miR-144-3p derived from BMSCs restrains the drug resistance of AML. Our study intends to assess miR-144-3p’s role in AML drug resistance. Drug resistance AML cells were transfected with miR-144-3p mimic or NC followed by measuring miR-144-3p level, relation of miR-144-3p with Wnt, cell activity and apoptosis by flow cytometry and the expression of signal proteins by Western Blot. The action of miR-144-3p in inducting drug resistance of K562/AND was more effective. Cell apoptosis and proliferative index was increased by overexpression of miR-144-3p along with significantly down regulated Wnt. In conclusion, the malignant invasion of AML with drug resistance is increased by miR-144-3p derived from BMSCs through regulating the Wnt/β-catenin signal, indicating that miT-144-3p might be a new target for the treatment of AML.